Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Novo Nordisk (CPSE:NOVO B) enters 2026 after a mixed stretch, with the share price showing a 20.3% decline over the past month and a modest 0.2% decline over the past 3 months.
Over longer periods, the stock is down 6.2% year to date and 45.7% over the past year, while the 5 year total return sits at 54.5%. That backdrop sets the stage for looking at how current fundamentals compare with this weaker recent share performance.
See our latest analysis for Novo Nordisk.
With the share price at DKK309.9 and a 1 month share price return of 20.3% decline alongside a 1 year total shareholder return of 45.7% decline, recent momentum looks weaker compared with the longer term picture.
If Novo Nordisk’s recent swings have you reassessing your exposure to healthcare, it could be a good moment to broaden your watchlist with 105 healthcare AI stocks.
So after a year where the share price has lagged its longer term record, with an indicated intrinsic value gap and analyst target above the current DKK309.9 level, is there a genuine buying opportunity here, or is the market already pricing in future growth?
Tokyo’s widely followed narrative puts Novo Nordisk’s fair value at DKK851.04 per share, far above the current DKK309.9. This frames the recent pullback in a very different light.
Novo Nordisk has built a formidable economic moat (“Burggraben”) through decades of expertise in diabetes care, world-class manufacturing, and a trusted global brand. With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform.
Curious how that moat, the obesity franchise, and future profitability tie together into one valuation story? The narrative leans on specific long term growth, margins, and a richer future earnings multiple to reach that DKK851.04 figure. The details behind those inputs are what make this view stand out.
Result: Fair Value of DKK851.04 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, that bullish story could be challenged if GLP-1 competition intensifies faster than expected, or if regulators push back harder on pricing and reimbursement.
Find out about the key risks to this Novo Nordisk narrative.
With sentiment clearly split between risk and reward, it makes sense to look at the full picture yourself and move quickly to shape your own view, starting with 4 key rewards and 5 important warning signs.
If Novo Nordisk has sharpened your focus, do not stop here. Broaden your hunting ground with a few targeted stock ideas that could refresh your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com